{"preliminary_commentary":{"by_channel":{"youtube":8,"x_thread":5,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06615479\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["arlocabtagene autoleucel (BMS-986393)"]],"indication":"lenalidomide-exposed relapsed or refractory multiple myeloma","name":"QUINTESSENTIAL-2","nct_id":"NCT06615479","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=quintessential-2-nct06615479. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Arm A","type":"EXPERIMENTAL"},{"description":null,"label":"Arm B","type":"ACTIVE_COMPARATOR"}],"collaborators":["Celgene Corporation"],"completion_date":{"date":"2032-06-22","type":"ESTIMATED"},"conditions":["Relapsed or Refractory Multiple Myeloma (RRMM)"],"enrollment":{"count":440,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"BMS-986393","otherNames":["Arlo-cel"],"type":"DRUG"},{"name":"Cyclophosphamide","otherNames":[],"type":"DRUG"},{"name":"Fludarabine","otherNames":[],"type":"DRUG"},{"name":"Daratumumab","otherNames":[],"type":"DRUG"},{"name":"Pomalidomide","otherNames":[],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Carfilzomib","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-29","lead_sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","official_title":"A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-12-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"Up to 5 years after the last participant is randomized"},{"measure":"Minimal residual disease (MRD)-negativity in complete response (CR)","timeFrame":"Up to 1 year after the last participant is randomized"}],"references":[],"start_date":{"date":"2025-03-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","url":"https://clinicaltrials.gov/study/NCT06615479"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/quintessential-2-nct06615479"}